Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-87890387 in Advanced Solid Tumors
NCT06178614Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2023
- Primary completion
- Mar 2027
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of JNJ-87890387 in solid tumor, sponsored by Janssen Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days and Adverse Events by Severity. Started Dec 2023; status: recruiting.
02
Drugs
JNJ-87890387
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06178614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06178614.